Literature DB >> 31691282

Strained, Photoejecting Ru(II) Complexes that are Cytotoxic Under Hypoxic Conditions.

John Roque1, Dmytro Havrylyuk2, Patrick C Barrett1, Tariq Sainuddin3, Julia McCain3, Katsuya Colón1, William T Sparks1, Evan Bradner1, Susan Monro3, David Heidary2, Colin G Cameron1, Edith C Glazer2, Sherri A McFarland1,3.   

Abstract

A series of strained Ru(II) complexes were studied for potential anticancer activity in hypoxic tissues. The complexes were constructed with methylated ligands that were photolabile and an imidizo[4,5-f][1,10]phenanthroline ligand that contained an appended aromatic group to potentially allow for contributions of ligand-centered excited states. A systematic variation of the size and energy of the aromatic group was performed using systems containing 1-4 fused rings, and the photochemical and photobiological behaviors of all complexes were assessed. The structure and nature of the aromatic group had a subtle impact on photochemistry, altering environmental sensitivity, and had a significant impact on cellular cytotoxicity and photobiology. Up to 5-fold differences in cytotoxicity were observed in the absence of light activation; this rose to 50-fold differences upon exposure to 453 nm light. Most significantly, one complex retained activity under conditions with 1% O2 , which is used to induce hypoxic changes. This system exhibited a photocytotoxicity index (PI) of 15, which is in marked contrast to most other Ru(II) complexes, including those designed for O2 -independent mechanisms of action.
© 2019 American Society for Photobiology.

Entities:  

Year:  2019        PMID: 31691282      PMCID: PMC7138741          DOI: 10.1111/php.13174

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  39 in total

1.  Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy.

Authors:  Jessica D Knoll; Claudia Turro
Journal:  Coord Chem Rev       Date:  2015-01-01       Impact factor: 22.315

2.  Why develop photoactivated chemotherapy?

Authors:  Sylvestre Bonnet
Journal:  Dalton Trans       Date:  2018-07-06       Impact factor: 4.390

Review 3.  Visible light photoredox catalysis with transition metal complexes: applications in organic synthesis.

Authors:  Christopher K Prier; Danica A Rankic; David W C MacMillan
Journal:  Chem Rev       Date:  2013-03-19       Impact factor: 60.622

4.  A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay.

Authors:  David K Heidary; Edith C Glazer
Journal:  Chembiochem       Date:  2014-01-31       Impact factor: 3.164

5.  Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window.

Authors:  Erin Wachter; David K Heidary; Brock S Howerton; Sean Parkin; Edith C Glazer
Journal:  Chem Commun (Camb)       Date:  2012-10-07       Impact factor: 6.222

6.  Light-driven machine prototypes based on dissociative excited states: photoinduced decoordination and thermal recoordination of a ring in a ruthenium(II)-containing [2]catenane.

Authors:  Pierre Mobian; Jean-Marc Kern; Jean-Pierre Sauvage
Journal:  Angew Chem Int Ed Engl       Date:  2004-04-26       Impact factor: 15.336

7.  Mechanistic study on the photochemical "light switch" behavior of [Ru(bpy)2dmdppz]2+.

Authors:  Erin Wachter; Edith C Glazer
Journal:  J Phys Chem A       Date:  2014-07-24       Impact factor: 2.781

8.  A ruthenium(II) complex capable of inducing and stabilizing bcl-2 G-quadruplex formation as a potential cancer inhibitor.

Authors:  Jingnan Zhang; Qianqian Yu; Qian Li; Licong Yang; Lanmei Chen; Yanhui Zhou; Jie Liu
Journal:  J Inorg Biochem       Date:  2013-12-24       Impact factor: 4.155

9.  Psoralen-deoxyribonucleic acid photoreaction. Characterization of the monoaddition products from 8-methoxypsoralen and 4,5'8-trimethylpsoralen.

Authors:  D Kanne; K Straub; H Rapoport; J E Hearst
Journal:  Biochemistry       Date:  1982-03-02       Impact factor: 3.162

10.  Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.

Authors:  Susan Monro; Katsuya L Colón; Huimin Yin; John Roque; Prathyusha Konda; Shashi Gujar; Randolph P Thummel; Lothar Lilge; Colin G Cameron; Sherri A McFarland
Journal:  Chem Rev       Date:  2018-10-08       Impact factor: 60.622

View more
  14 in total

1.  Ruthenium Photosensitizers for NIR PDT Require Lowest-Lying Triplet Intraligand (3IL) Excited States.

Authors:  Liubov M Lifshits; John A Roque; Elamparuthi Ramasamy; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal:  J Photochem Photobiol       Date:  2021-09-15

2.  Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model.

Authors:  Quanchi Chen; Jordi-Amat Cuello-Garibo; Ludovic Bretin; Liyan Zhang; Vadde Ramu; Yasmin Aydar; Yevhen Batsiun; Sharon Bronkhorst; Yurii Husiev; Nataliia Beztsinna; Lanpeng Chen; Xue-Quan Zhou; Claudia Schmidt; Ingo Ott; Martine J Jager; Albert M Brouwer; B Ewa Snaar-Jagalska; Sylvestre Bonnet
Journal:  Chem Sci       Date:  2022-05-16       Impact factor: 9.969

3.  Anticancer Agent with Inexplicable Potency in Extreme Hypoxia: Characterizing a Light-Triggered Ruthenium Ubertoxin.

Authors:  Houston D Cole; John A Roque; Ge Shi; Liubov M Lifshits; Elamparuthi Ramasamy; Patrick C Barrett; Rachel O Hodges; Colin G Cameron; Sherri A McFarland
Journal:  J Am Chem Soc       Date:  2021-12-09       Impact factor: 16.383

Review 4.  Factors that influence singlet oxygen formation vs. ligand substitution for light-activated ruthenium anticancer compounds.

Authors:  Elizabeth T Papish; Olaitan E Oladipupo
Journal:  Curr Opin Chem Biol       Date:  2022-04-25       Impact factor: 8.972

5.  Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy.

Authors:  John A Roque; Patrick C Barrett; Houston D Cole; Liubov M Lifshits; Evan Bradner; Ge Shi; David von Dohlen; Susy Kim; Nino Russo; Gagan Deep; Colin G Cameron; Marta E Alberto; Sherri A McFarland
Journal:  Inorg Chem       Date:  2020-10-30       Impact factor: 5.165

6.  Singlet Oxygen Formation vs Photodissociation for Light-Responsive Protic Ruthenium Anticancer Compounds: The Oxygenated Substituent Determines Which Pathway Dominates.

Authors:  Fengrui Qu; Robert W Lamb; Colin G Cameron; Seungjo Park; Olaitan Oladipupo; Jessica L Gray; Yifei Xu; Houston D Cole; Marco Bonizzoni; Yonghyun Kim; Sherri A McFarland; Charles Edwin Webster; Elizabeth T Papish
Journal:  Inorg Chem       Date:  2021-02-03       Impact factor: 5.165

7.  Fine-Feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer Activity.

Authors:  Houston D Cole; John A Roque; Liubov M Lifshits; Rachel Hodges; Patrick C Barrett; Dmytro Havrylyuk; David Heidary; Elamparuthi Ramasamy; Colin G Cameron; Edith C Glazer; Sherri A McFarland
Journal:  Photochem Photobiol       Date:  2021-03-28       Impact factor: 3.521

8.  NIR-Absorbing RuII Complexes Containing α-Oligothiophenes for Applications in Photodynamic Therapy.

Authors:  Liubov M Lifshits; John A Roque; Houston D Cole; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal:  Chembiochem       Date:  2020-09-25       Impact factor: 3.164

Review 9.  Biological activities of polypyridyl-type ligands: implications for bioinorganic chemistry and light-activated metal complexes.

Authors:  Austin C Hachey; Dmytro Havrylyuk; Edith C Glazer
Journal:  Curr Opin Chem Biol       Date:  2021-03-30       Impact factor: 8.822

10.  Chiral resolution and absolute configuration determination of new metal-based photodynamic therapy antitumor agents.

Authors:  Daniel W Armstrong; Jeongjae Yu; Houston D Cole; Sherri A McFarland; Jordan Nafie
Journal:  J Pharm Biomed Anal       Date:  2021-06-29       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.